The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index; 2 of the 6 sources its claims cite were checked for support.
Xpert MTB/RIF for Rapid Diagnosis of Tuberculous Lymphadenitis from Fine-Needle-Aspiration Biopsy Specimens
Open accessAbstract
This study demonstrates the excellent diagnostic accuracy of the Xpert MTB/RIF test in patients with tuberculous lymphadenitis. The test sensitivity and specificity were 96.7% (95% confidence interval [CI], 86.6 to 100%) and 88.9% (95% CI, 69.6 to 100%), respectively, and it correctly identified 6/6 (100%) of the cytology smear-negative/culture-positive cases and 1 of 2 (50%) rifampin-resistant cases.
Overview
CoChat Summary
TL;DR
Xpert MTB/RIF showed high diagnostic accuracy for tuberculous lymphadenitis using fine-needle-aspiration biopsy specimens, with rapid results compared with culture. It detected all six smear-negative/culture-positive cases but only one of two rifampin-resistant cases.
Key findings
- Against the composite reference standard, Xpert MTB/RIF sensitivity was 96.7% (29/30; 95% CI, 86.6 to 100%) and specificity was 88.9% (16/18; 95% CI, 69.6 to 100%).
- Xpert MTB/RIF was positive in 6/6 (100%) smear-negative/culture-positive cases and identified 1 of 2 (50%) rifampin-resistant cases.
- Average time to microbiological culture result was 18.5 days (range, 9 to 55 days), whereas Xpert MTB/RIF results were available within 2 h of test commencement.
- Among 48 patients with adequate smears, cytomorphological features associated with TB were seen in 32 (66.7%); HIV status was positive in 9 (18.8%), negative in 3 (6.6%), and unknown in 36 (75%).
Methods
- Diagnostic accuracy study of 50 consenting patients referred for fine-needle aspiration biopsy (FNAB) with possible mycobacterial lymphadenitis; 48 cases had adequate smears for diagnosis and were analyzed.
- FNAB was performed with two passes; smears were used for cytology, Ziehl-Neelsen staining, and Papanicolaou stain-induced fluorescence microscopy. Residual aspirate material was used for MGIT 960 mycobacterial culture, with MTBDRplus genotypic drug susceptibility testing on positive cultures, and the remaining aspirate was processed for Xpert MTB/RIF.
- Performance was calculated using Statistica version 8, comparing Xpert MTB/RIF to a reference standard of positive cytology (cytomorphology consistent with mycobacterial infection plus direct organism visualization) and/or culture positive for *M. tuberculosis*.
Limitations
- The paper states that limitations include the small number of rifampin-resistant cases identified and that the research was conducted in a referral center, whereas the technique is ideally suited to peripheral laboratories.
- Evident from the text: only 48 patients were analyzed, only 2 rifampin-resistant cases were identified, and HIV status was unknown for 36/48 patients (75%).
- Evident from the text: one possible false-negative Xpert result had a prolonged 9-day transit interval before testing, and one false-positive result occurred in an epithelial inclusion cyst with no known explanation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
2 Valid · 0 Not valid · 2 Not checked · 15 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In that study, the combined sensitivity and specificity of 77.3% and 98.2% were reported, respectively.”
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The Results (Table 2) report 77.3% sensitivity and 98.2% specificity for all extrapulmonary specimen types combined, as the printed citing sentence states. The claim's added restriction to tissue is not supported: Table 2 gives tissue-specific values of 69.0% and 98.4%. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The test sensitivity and specificity were 96.7% (95% confidence interval [CI], 86.6 to 100%) and 88.9% (95% CI, 69.6 to 100%), respectively”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The test sensitivity and specificity were 96.7% (95% confidence interval [CI], 86.6 to 100%) and 88.9% (95% CI, 69.6 to 100%), respectively”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“it correctly identified 6/6 (100%) of the cytology smear-negative/culture-positive cases”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The cytomorphology from one of the false-positive results showed a necrotizing suppurative lymphadenitis, which is consistent with TB.”
plainstates an associationSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 19 claims and every source verdict.
- It may state two separate claims as one. 4
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, the sensitivity of Xpert in the current study is lower than what was found in similar study by Ligthelm et al (sensitivity, 96.7%) [22].”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“The specificity (91%) of the Xpert in the current study was found to be consistent with previous studies reported by others (specificity, 89–99%) [20,21,22], but higher than the study done by Biadigilegn et al (specificity, 69.2%) [13].”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“In agreement with other studies [9,18,22], Xpert has a higher sensitivity than smear microscopy.”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Negative 3 6.6”
Reported 6.6 · recomputed 6.25
Citations
Cites
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309
Self-citationExtrapulmonary tuberculosis: an overview.
Golden, M., & Vikram, H. R. (2005) · PubMed · Cited by 1,033
Boehme, C. C., Nicol, M. P., Nabeta, P., Michael, J. S., Gotuzzo, E., Tahirli, R., Gler, M. T., Blakemore, R., Worodria, W., Gray, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60438-8 · Cited by 1,013
Self-citationHelb, D., Jones, M., Story, E., Boehme, C., Wallace, E., Ho, K., Kop, J., Owens, M. R., Rodgers, R., Banada, P., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01463-09 · Cited by 914
Extra Pulmonary Tuberculosis: An Overview
J. Cantres-Fonseca, O., Rodriguez-Cintrón, W., Del Olmo-Arroyo, F., & Baez-Corujo, S. (2019) · Role of Microbes in Human Health and Diseases · doi:10.5772/intechopen.81322 · Cited by 514
Extrapulmonary tuberculosis: an overview
Ramírez-Lapausa, M., Menéndez-Saldaña, A., & Noguerado-Asensio, A. (2015) · Cited by 478
Rapid Molecular Detection of Extrapulmonary Tuberculosis by the Automated GeneXpert MTB/RIF System
Hillemann, D., Rüsch-Gerdes, S., Boehme, C., & Richter, E. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02268-10 · Cited by 413
Barnard, M., Albert, H., Coetzee, G., O'Brien, R., & Bosman, M. E. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1436oc · Cited by 391
Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs
Barrera, L., Cooreman, E., de Dieu Iragena, J., et al. (2008) · Cited by 227
The spectrum of disease in children treated for tuberculosis in a highly endemic area.
Marais, B. J., Gie, R. P., Schaaf, H. S., Hesseling, A. C., Enarson, D. A., & Beyers, N. (2006) · PubMed · Cited by 177
Self-citation
Research works printed but not linked: 1
- LeimanG. 1995. The registered nurse as aspirator: experience in a busy cytopathology unit. Acta Cytol. 39:1010.
Cited by
Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
Steingart, K. R., Schiller, I., Horne, D. J., Pai, M., Boehme, C. C., & Dendukuri, N. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009593.pub3 · Cited by 1,102
Denkinger, C. M., Schumacher, S. G., Boehme, C. C., Dendukuri, N., Pai, M., & Steingart, K. R. (2014) · European Respiratory Journal · doi:10.1183/09031936.00007814 · Cited by 527
Lawn, S. D., Mwaba, P., Bates, M., Piatek, A., Alexander, H., Marais, B. J., Cuevas, L. E., McHugh, T. D., Zijenah, L., Kapata, N., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70008-2 · Cited by 458
Self-citationScaling up interventions to achieve global tuberculosis control: progress and new developments
Raviglione, M., Marais, B., Floyd, K., Lönnroth, K., Getahun, H., Migliori, G. B., Harries, A. D., Nunn, P., Lienhardt, C., Graham, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60727-2 · Cited by 340
Self-citationClinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis
Tortoli, E., Russo, C., Piersimoni, C., Mazzola, E., Dal Monte, P., Pascarella, M., Borroni, E., Mondo, A., Piana, F., Scarparo, C., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00176311 · Cited by 322
Metadata
- Authors
- Ligthelm, L. J., Nicol, M. P., Hoek, K. G. P., Jacobson, R., van Helden, P. D., Marais, B. J., Warren, R. M., & Wright, C. A.
- Affiliations
- National Health Laboratory Service (ZA)
- DST/NRF Centre of Excellence for Biomedical Tuberculosis Research/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics of the Department of Biomedical Sciences, Faculty of Health Sciences Stellenbosch University, Tygerberg, Cape Town, South Africa
- The University of Sydney (AU)
- Stellenbosch University (ZA)
- Corresponding author
- Ligthelm, Louis J.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2011-11
- Volume
- 49
- Issue
- 11
- Pages
- 3967-3970
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC3209093
- OpenAlex
- W2171353099
- Cited by
- 123
- References
- 16
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 5 · 2023: 8 · 2022: 7 · 2021: 15 · 2020: 9 · 2019: 11 · 2018: 6 · 2017: 6 · 2016: 3 · 2015: 8 · 2014: 15 · 2013: 7 · 2012: 15
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- SUNScholar (Stellenbosch University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Diagnosis and treatment of tuberculosis
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Keywords
- Xpert MTB/RIF, tuberculous lymphadenitis, Mycobacterium tuberculosis, rapid molecular diagnostics, fine-needle aspiration, diagnostic accuracy, sensitivity and specificity, rifampicin resistance, smear-negative tuberculosis, culture-positive tuberculosis
- MeSH terms
- Adolescent, Adult, Antitubercular Agents, Bacteriological Techniques, Child, Child, Preschool, Female, Humans, Male, Mycobacterium tuberculosis, Reagent Kits, Diagnostic, Rifampin, Sensitivity and Specificity, Tuberculosis, Lymph Node, Drug Resistance, Bacterial, Molecular Diagnostic Techniques, Biopsy, Fine-Needle, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Xpert MTB/RIF for Rapid Diagnosis of Tuberculous Lymphadenitis from Fine-Needle-Aspiration Biopsy Specimens. https://app.cochat.ai/papers/10.1128/jcm.01310-11
- The paper
- Ligthelm, L. J., Nicol, M. P., Hoek, K. G. P., Jacobson, R., van Helden, P. D., Marais, B. J., Warren, R. M., & Wright, C. A. (2011). Xpert MTB/RIF for Rapid Diagnosis of Tuberculous Lymphadenitis from Fine-Needle-Aspiration Biopsy Specimens. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01310-11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.